Detalles de la búsqueda
1.
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells.
Cytotherapy
; 2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727653
2.
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Am J Hematol
; 99(7): 1250-1256, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38778766
3.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Lancet Oncol
; 24(8): 913-924, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37414060
4.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Haematologica
; 108(1): 110-121, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770532
5.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Am J Hematol
; 98(11): 1699-1710, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37584447
6.
Primary Cutaneous Marginal Zone Lymphoproliferative Disorder of Donor Origin after Allogeneic Hematopoietic Stem Cell Transplantation.
Am J Dermatopathol
; 45(6): 378-382, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37130208
7.
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Ann Hematol
; 101(9): 2053-2067, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35780254
8.
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Am J Hematol
; 97(1): 30-42, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34695229
9.
Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH).
Eur J Haematol
; 106(6): 842-850, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33713387
10.
Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH).
Clin Transplant
; 35(5): e14255, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33595866
11.
Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
J Clin Apher
; 36(5): 697-710, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34185332
12.
Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.
Br J Haematol
; 188(5): 745-756, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31498883
13.
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(9): 1703-1712, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31054983
14.
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
Haematologica
; 104(5): 929-936, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30655377
15.
Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study.
Biol Blood Marrow Transplant
; 24(11): 2265-2270, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30031070
16.
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .
Biol Blood Marrow Transplant
; 24(5): 964-972, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29305194
17.
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Blood
; 127(9): 1151-62, 2016 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26668134
18.
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Eur J Haematol
; 101(3): 332-339, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846964
19.
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Am J Hematol
; 93(6): 736-744, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498106
20.
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(8): 1127-1136, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27402145